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ABSTRACT
Objectives To investigate the respective associations
and clinical usefulness of the metabolic syndrome
(MetS) and its individual components to predict the risk
of ﬁrst coronary heart disease (CHD) events in elderly.
Design The Three-City is a French prospective multisite
community-based cohort.
Setting Three large French cities: Bordeaux, Dijon and
Montpellier.
Participants 7612 subjects aged 65 and over who were
free of CHD at baseline.
Main outcome measures The MetS was deﬁned by
the 2005 National Cholesterol Education Program Adult
Treatment Panel III criteria.
Results During a median follow-up of 5.2 years, 275
ﬁrst CHD events were adjudicated. The MetS was
associated with increased risks of total (adjusted HR:
1.78; 95% CI 1.39 to 2.28), fatal (HR: 2.40; 95% CI 1.41
to 4.09) and non-fatal (HR: 1.64; 95% CI 1.24 to 2.17)
CHD events. The association with total CHD was
signiﬁcant in women (HR: 2.56; 95% CI 1.75 to 3.75)
but not in men (HR: 1.39; 95% CI 0.99 to 1.94; p for
interaction¼0.012). When in the same multivariable
model, hyperglycemia and abdominal adiposity in
women, hyperglycemia, lower HDL cholesterol and
abdominal adiposity (inverse association) in men were
the components signiﬁcantly associated with CHD. The
components of the MetS but not the MetS itself
improved risk prediction beyond traditional risk factors
(NRI¼ 9.35%, p<0;001).
Conclusion The MetS is a risk marker for CHD in
community-dwelling elderly subjects but may not be
useful for CHD risk prediction purposes compared to its
individual components.
INTRODUCTION
The metabolic syndrome (MetS) has been widely
associated with incident type II diabetes, cardio-
vascular disease (CVD) and total mortality risks
primarily in the middle-aged.
1e4 The incidence rate
of CHD and the prevalence of the MetS both
increase with age, suggesting that assessing the
association between the MetS and CHD risk in
elderly may have public health implications. In
a recent cross-sectional analysis of the Three City
Study involving French community-based older
adults, participants with the MetS at baseline had
higher degree of subclinical atherosclerosis as
measured by the presence of carotid plaques and
intima-media thickness.
5 This suggests that the
MetS may be a risk marker for CHD in older adults.
So far however, this issue has been addressed by
only few studies.
6e9 Except the Cardiovascular
Health Study, these studies covered a restricted age
range (60e79 years or 70e79 years) and in one
study, participants were all women.
6e9 Most
studies used the 2001 NCEP ATP III criteria
although signiﬁcant changes and new deﬁnitions
occurred since 2005.
10e13 The impact of these
changes on the association between the MetS and
subsequent CHD has yet not been systematically
evaluated in the elderly population. Moreover, there
is still controversy as to whether the MetS adds
predictive information for CHD risk beyond its
individual components. This is a major question as
it raises the clinical usefulness of the MetS.
Therefore, our aims were ﬁrst to quantify the
associations between the MetS and its individual
components with the risk of CHD and second to
evaluate the added value of the MetS for CHD risk
prediction beyond its individual components. These
two issues were addressed in older men and women
who were participants of the Three City Study.
14
METHODS
Study population
The Three-City Study is a French multicentre
prospective cohort investigating the determinants
of CHD, stroke and dementia in community-
dwelling elderly. Details of the protocol have been
previously described.
14 Brieﬂy, community-
dwellers aged 65 years and over were selected from
the electoral rolls of three large cities and then
invited to participate in the study. Overall, 9294
subjects (3649 men and 5645 women) agreed to
participate in the study including 2104 from
Bordeaux (South-West), 4931 from Dijon (North-
East) and 2259 from Montpellier (South). The
study protocol had been approved by the Ethical
Committee of the University Hospital of Kremlin-
Bicêtre. Each participant had signed an informed
consent.
< Additional ﬁgures and tables
are published online only. To
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EpidemiologyBaseline data collection and examination
Trained interviewers conducted face-to-face interviews, using
a standardised questionnaire. A wide range of information was
collected including demographic characteristics, educational
level, occupation, daily life habits such as smoking and alcohol
consumption and functional status. Past history of CHD
included history of angina pectoris, myocardial infarction or
revascularisation procedure (percutaneous transluminal angio-
plasty or coronary bypass graft surgery). Information on all
medications they had regularly used in the past month was also
recorded. Brachial blood pressure was measured twice after at
least 5 min of rest in a seated position, with an appropriately
sized cuff placed on the right arm, using a validated digital
electronic tensiometer (OMRON M4, OMRON Corp., Kyoto,
Japan). Height and weight were measured in a subject in a light
dressing. Blood was collected following overnight fasting and
centralised standard measurements of lipids and glucose levels
were performed. Diabetes was deﬁned as a fasting blood glucose
level $7 mmol/l and/or drug treatment for diabetes. LDL
cholesterol level was calculated using Friedewald equation for
triglycerides values #4.5 g/l.
MetS deﬁnitions
The main analysis was performed using the 2005 revised
National Cholesterol Education Program Adult Treatment Panel
III (NCEP ATP III) deﬁnition (11), requiring the presence of at
least three of the following criteria: abdominal obesity (waist
circumference $102 cm in men and $88 cm in women);
triglycerides level $150 mg/dl (1.7 mmol/l) or nicotinic acid or
ﬁbrate treatment; HDL cholesterol level <40 mg/dl (1.0 mmol/l)
in men and <50 mg/dl (1.3 mmol/l) in women or nicotinic
acid or ﬁbrate treatment; fasting glycaemia $100 mg/dl
(5.6 mmol/l) or medication for diabetes; systolic blood pressure
$130 mm Hg or diastolic blood pressure $85 mm Hg or anti-
hypertensive medication use. In additional analyses, the Inter-
national Diabetes Federation (IDF) deﬁnition and the original
2001 NCEP ATP III criteria were used for comparisons.
10 12
Follow-up and CHD events ascertainment
At each follow-up visit, subjects were asked to report any new
severe medical event or hospitalisation since the last contact. For
all subjects reporting a possible CHD event, all available clinical
information was collected including emergency medical service
and hospitalisation reports, interview with the patient’s physi-
cian or the family. CHD events were validated by an indepen-
dent expert committee. CHD was deﬁned as hospitalised angina
pectoris, hospitalised myocardial infarction, CHD death (I210-
I219, I251-I259 and I461 ICD-10 codes), or revascularisation
(percutaneous intervention or coronary artery bypass-grafting).
Incident CHD status was known for 97% of the participants.
Statistical analysis
The baseline characteristics were compared according to the
presence of the MetS using c
2 tests (or Fisher’s exact test when
appropriate) and Student tests for categorical and continuous
variables respectively. Cox proportional hazard regression was
used to estimate the HRs of the MetS for CHD over 6 years.
HRs were adjusted for age, gender, study center, educational
level (<9, 9e11, $12 years), living alone, incapacity in IADL,
smoking status (never, former, current), LDL cholesterol level
and statin treatment on an a priori basis. Analysis was
performed in the whole cohort and by gender. An interaction
term between gender and the MetS was included in the model
and the Wald test was used to evaluate the statistical signiﬁ-
cance of the interaction term. To identify the criteria of the
MetS the most predictive of CHD events, all components of
the MetS were considered in a single model together with the
baseline confounders mentioned above. To assess the respective
association of the MetS and its individual components with
CHD, all the components of the MetS and the MetS were then
included in the same model together with the baseline
confounders. In additional analyses, the analyses were repeated
using either the IDF or the 2001 NCEP criteria. The added value
of the MetS for CHD risk prediction was quantiﬁed by calcu-
lating net reclassiﬁcation improvement (NRI) between the risk
factors base model that included age, gender, study center,
educational level (<9, 9e11, $12 years), living alone, incapacity
in IADL, smoking status (never, former, current), LDL choles-
terol level and statin treatment, and the ‘novel’ model addi-
tionally including the MetS.
15 For comparison, we also
calculated the NRI between the risk factors base model and
a model additionally including the ﬁve components of the MetS
in their continuous form. We used the 10-year Framingham
CHD risk categories (<10%, 10%e20% and over 20%) interpo-
lated to 6 years of follow-up (<6%, 6%e12% and over 12%) to
compute the NRI. We also calculated the Harell-C index, an
extension of the area under the receiving operating curves suited
for censored data, to separately estimate whether the addition of
the MetS and of its individual components increased the
discrimination ability of the risk factors base model.
16 The 95%
CIs of the Harell-C indexes of each model together with differ-
ences between the Harell-C indexes, were internally validated by
bootstrapping with 1000 replications. The proportional hazards
assumption of the Cox proportional hazard model was checked
using Schoenfeld’s global test. All statistical tests were two-
sided using a type I error of 0.05. Analyses were computed using
STATA
 (release 11).
RESULTS
Baseline characteristics
Of the 9294 study participants, 1114 were excluded since they
had a personal history of CHD at baseline (n¼1105) or had their
baseline CHD status unknown (n¼9). There were 568 additional
subjects with missing information on the MetS status at base-
line. They were 3 years older on average, more often women,
alone, hypertensive, diabetics, less educated, and had higher
mean triglycerides and lower mean HDL cholesterol than the
7612 subjects with available MetS at baseline (Flow chart on
supplemental ﬁgure 1).
The median age of the 7612 participants was 73.2 years (inter
quartile range: 69.5e77.4) and 63% were women. The MetS as
deﬁned by the 2005-revised NCEP ATP III criteria was present in
29.2% of the participants, 29.4% in women and 28.9% in men.
The baseline characteristics of the participants according to the
presence of the MetS are reported in table 1 separately in women
and men.
Association between the MetS and new CHD events
During a median follow-up of 5.2 years, 110 subjects with the
MetS (10 with revascularisation, 39 with angina, 33 with
myocardial infarction and 28 with fatal CHD) and 165 without
the MetS (two with revascularisation, 67 with angina, 66 with
myocardial infarction, and 30 with fatal CHD) experienced
a ﬁrst CHD event. This yielded a mean annual CHD incidence
rate of 10.63 (95% CI 8.67 to 12.81) per 1000 person-years in
subjects with the MetS compared to 6.40 (95% CI 5.49 to 7.45)
per 1000 person-years in subjects without the MetS (p<0.001).
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EpidemiologyCHD incidence rates were signiﬁcantly higher in subjects with
compared to subjects without the MetS in women only
(Supplemental ﬁgure 2).
As shown in table 2, in multivariate adjusted analysis,
subjects with the MetS had a signiﬁcant increased risk of total
CHD (HR: 1.78; 95% CI 1.39 to 2.28), fatal CHD (HR: 2.40; 95%
CI 1.41 to 4.09) and non-fatal CHD events (HR: 1.64; 95% CI
1.24 to 2.17). There was a signiﬁcant quantitative interaction
with gender: the multivariable HRs for total CHD were 2.56
(95% CI 1.75 to 3.75) in women compared to 1.39 (95% CI 0.99
to 1.94) in men (p for interaction: 0.012). After excluding
subjects with type 2 diabetes at baseline (n¼665; 62 CHD
events), the association with the MetS remained highly signiﬁ-
cant for fatal CHD events in the overall cohort and in women.
Respective association of the MetS and its components with
new CHD events
As shown in ﬁgure 1, when all the MetS components were in the
same Cox model together with baseline confounders, elevated
fasting glycaemia (HR: 2.22; 95% CI 1.69 to 2.92) and lower
HDL cholesterol (HR: 1.52; 95% IC: 1.06-2.18) were the criteria
signiﬁcantly associated with total CHD events in the overall
cohort. In women, they were elevated fasting glycaemia
(HR¼2.47; 95% CI 1.56 to 3.87) and elevated abdominal
adiposity (HR¼1.57; 95% IC: 1.03-2.41). In men they were
elevated fasting glycaemia (HR¼2.04; 95% CI 1.45 to 2.87),
lower HDL cholesterol (HR¼1.72; 95% CI 1.06 to 2.79) and
elevated abdominal adiposity (HR¼0.59; 95% CI 0.39 to 0.90).
After further adjustment for the MetS, the signiﬁcant compo-
nents and the magnitude of their association with CHD
remained the same whereas the MetS was no longer associated
with CHD (HR: 0.89; 95% CI 0.53 to 1.49) in the overall cohort.
The same ﬁndings were observed in analyses stratiﬁed by gender
(not shown).
Improvement in discrimination for CHD risk associated with the
MetS and its components
As shown in table 3, adding the MetS to a risk factors base
model that comprised age, gender, study center, educational
level, living alone, incapacity in IADL, smoking status, LDL
cholesterol and statin treatment modestly improved discrimi-
nation, that is, the capacity to differentiate those who will
suffer a CHD event from those who will not, since 3.12% of the
individuals were reclassiﬁed in adequate risk categories (p¼0.06).
By contrast, adding the components of the MetS (in their
continuous form) signiﬁcantly improved discrimination of the
risk factors base model, since 9.35% of the individuals were
reclassiﬁed in adequate risk categories (p<0.001). Similarly,
adding the MetS to the risk factors base model marginally
improved the value of the Harell-C-index (from 0.706 to 0.718)
contrary to the addition of the individual components of the
MetS (from 0.706 to 0.761).
Additional MetS deﬁnitions
The frequency of the MetS remained similar when the IDF
deﬁnition was used (28.6%) but was of 14.2% when the 2001
Table 1 Baseline characteristics by gender according to the presence of the MetS*
Women Men
No MetS MetS
py
No MetS MetS
py n[3,367 n[1,400 n[2,022 n[823
Age, years 73.7 (5.4) 74.3 (5.2) 0.0003 73.8 (5.5) 73.6 (5.2) 0.457
Educational level
<9 years 1105 (32.9) 561 (40.1) <0.001 532 (26.3) 281 (34.2) <0.001
9e11 years 1081 (32.1) 477 (34.1) 529 (26.2) 220 (26.8)
$12 years 1178 (35.0) 361 (25.8) 960 (47.5) 321 (39.1)
Living alone 1593 (47.5) 701 (50.2) 0.087 283 (14.0) 109 (13.3) 0.596
Incapacity (IADL) 294 (8.8) 159 (11.4) 0.005 140 (7.0) 62 (7.6) 0.572
Smoking status
Never smoking 2720 (80.8) 1151 (82.3) 0.484 676 (33.4) 223 (27.2) 0.002
Former smoking 503 (14.9) 195 (13.9) 1162 (57.5) 530 (64.6)
Current smoking 143 (4.3) 53 (3.8) 184 (9.1) 68 (8.3)
Number of pack-yearsz 16.8 (18.8) 18.5 (22.2) 0.263 23.4 (21.4) 26.2 (22.7) 0.011
BMI, kg/m
2 24.3 (3.8) 27.7 (4.7) <0.0001 25.3 (3.0) 28.0 (3.7) <0.0001
Hypertension 2256 (67.0) 1223 (87.4) <0.001 1546 (76.5) 753 (91.5) <0.001
Diabetes 58 (1.7) 260 (19.2) <0.001 119 (5.9) 228 (28.4) <0.001
Statin treatment 541 (16.1) 147 (10.5) <0.001 244 (12.1) 89 (10.8) 0.346
Anti-hypertensive drug(s) 1319 (39.2) 895 (63.9) <0.001 775 (38.3) 483 (58.7) <0.001
Aspirin treatment 438 (13.0) 198 (14.2) 0.285 325 (16.1) 151 (18.5) 0.129
MetS criteria
Abdominal obesity criteria 669 (21.2) 851 (65.7) <0.001 273 (14.4) 437 (57.4) <0.001
Triglycerides criteria 241 (7.2) 1128 (80.9) <0.001 205 (10.1) 636 (77.6) <0.001
HDL chol. criteria 186 (5.5) 1052 (75.5) <0.001 47 (2.3) 501 (61.1) <0.001
Glucose criteria 153 (4.6) 515 (38.2) <0.001 243 (12.0) 449 (56.0) <0.001
Blood pressure criteria 2633 (78.2) 1356 (96.9) <0.001 1749 (86.5) 808 (98.2) <0.001
The Three-City Study.
The age and study center adjusted cumulative hazard of ﬁrst CHD events were plotted by baseline MetS status and by gender and were derived from a Cox proportional hazard regression
model. Results are numbers (%) or means (SDs) for qualitative or quantitative data respectively.
*MetS as deﬁned by the revised 2005 National Cholesterol Education Program Adult Treatment Panel III criteria.
yp Value are based on c
2 (or Fisher exact) or Student tests for qualitative or quantitative data respectively. Compared groups are Mets versus no Mets.
zNumber of pack-years in current or former smokers.
BMI, Body Mass Index; CHD, coronary heart disease; chol, cholesterol; HDL, High-Density Lipoprotein; IADL, Instrumental Activity of Daily Living; LDL, Low-Density Lipoprotein; MetS,
Metabolic syndrome.
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EpidemiologyNCEP ATP III criteria were employed. By contrast associations
with CHD were of comparable magnitude whatever the MetS
deﬁnitions used (Supplemental table 1).
DISCUSSION
In this large prospective cohort of community-dwelling subjects
aged 65 and over the MetS as deﬁned by the revised 2005 NCEP
ATP III was associated with an 80% increased risk of total CHD
events independently of baseline confounders, with a signiﬁ-
cantly stronger association in women compared to men.
However, the MetS failed to improve signiﬁcantly discrimina-
tion for CHD risk, contrary to its individual components.
With the Cardiovascular Health Study, this is the sole
community based cohort of elderly subjects covering a wide
range of age over 65 years.
6 Remaining studies covered
a narrowed age range, 70e79 years in the Health Ageing and
Body Composition Study, 65e74 years in a Finn study and
60e79 years in the British Women’s Heart and Health Study.
7e9
Most previous studies used the MetS as deﬁned by the 2001
NCEP ATP III criteria in which treatments for hypertension,
dyslipidemia and hyperglycemia are not considered. Elderly
subjects represent a highly treated population and exclusion of
these treatments may affect the frequency of the MetS and the
strength of its association with CHD events in this population.
As shown here, the frequency of the MetS was twice less
Table 2 Incidence rates of CHD and HRs of the MetS* for CHD
Total Women Men
Total cohort n[7612 n[4767 n[2845
Total CHD events 275 112 163
Incidence rate/1000 PY (95% CI) 7.6 (6.8 to 8.6) 4.8 (4.0 to 5.8) 12.5 (10.7 to 14.6)
HRy (95% CI) 1.78 (1.39 to 2.28) 2.56 (1.75 to 3.75) 1.39 (0.99 to 1.94)
Fatal CHD events 58 25 33
Incidence rate/1000 PY (95% CI) 1.6 (1.2 to 2.1) 1.1 (0.7 to 1.6) 2.5 (1.8 to 3.6)
HRy (95% CI) 2.40 (1.41 to 4.09) 3.89 (1.65 to 9.19) 1.69 (0.82 to 3.47)
Non-fatal CHD events 217 87 130
Incidence rate/1000 PY (95% CI) 6.0 (5.3 to 6.9) 3.8 (3.0 to 4.6) 10.0 (8.4 to 11.9)
HRy (95% CI) 1.64 (1.24 to 2.17) 2.30 (1.49 to 3.53) 1.31 (0.90 to 1.91)
Non-diabetic n[6869 n[4393 n[2476
Total CHD events 209 84 125
Incidence rate/1000 PY (95% CI) 6.3 (5.5 to 7.3) 3.9 (3.2 to 4.8) 10.9 (9.1 to 13.0)
HRy (95% CI) 1.15 (0.84 to 1.57) 1.52 (0.96 to 2.42) 0.93 (0.60 to 1.44)
Fatal CHD events 45 19 26
Incidence rate/1000 PY (95% CI) 1.4 (1.0 to 1.8) 0.9 (0.6 to 1.4) 2.3 (1.5 to 3.3)
HRy (95% CI) 2.23 (1.20 to 4.14) 3.09 (1.19 to 8.02) 1.77 (0.76 to 4.12)
Non-fatal CHD events 164 65 99
Incidence rate/1000 PY (95% CI) 5.0 (4.3 to 5.8) 3.0 (2.4 to 3.9) 8.6 (7.1 to 10.5)
HRy (95% CI) 0.94 (0.65 to 1.36) 1.21 (0.70 to 2.10) 0.78 (0.47 to 1.30)
The Three-City Study.
*As deﬁned by the revised 2005 National Cholesterol Education Program Adult Treatment Panel III criteria.
yHRs from Cox proportional hazard models adjusted for age, study center, educational level, living alone, incapacity in instrumental
activities of daily living, smoking status, LDL cholesterol, statin treatment, and gender when appropriate.
CHD, coronary heart disease; MetS, Metabolic syndrome; PY, Person-Years.
Figure 1 Mutually adjusted HRs of the
individual components of the MetS* for
CHD. The Three City Study.
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Epidemiologyfrequent using the 2001 NCEP ATP III criteria compared to the
2005 ATP criteria or the IDF deﬁnition that include treatments.
By contrast, there was little variation in CHD risk between the
2001 NCEP ATP III deﬁnition, the 2005 revised NCEP ATP III
deﬁnition or the IDF deﬁnition in the current study.
The current study suggests that the association of the MetS
with CHD was stronger for fatal than non-fatal CHD events.
The inclusion of revascularisation in the deﬁnition of non-fatal
events may have reduced their association with the MetS.
However, excluding revascularisation from the deﬁnition of non-
fatal events did not change this pattern of association (not
shown). Moreover, this may reﬂect a particular association with
sudden arrhythmic death as previously shown in middle-
aged men.
17 The possibility that subjects with the MetS have
more severe coronary artery lesions (which may increase their
risk of CHD death) is not currently supported by angiographic
ﬁndings.
18 19
We found a stronger association between the MetS and CHD
in women compared to men with a highly signiﬁcant gender
interaction. This has been previously observed in the middle-
aged population and has been conﬁrmed in two recent meta-
analyses.
3 4 More conﬂicting results on this issue has been
reported in the elderly.
6e9 The putative reasons for this gender
interaction remain unclear. The stronger association between
type 2 diabetes and CHD in women compared to men has been
advocated.
20 21 In the current study however, this gender
interaction persisted after the exclusion of subjects with type 2
diabetes at baseline. Second, abdominal adiposity may
contribute to this gender interaction as it was predictive of CHD
in women and inversely associated with CHD in men. While
this intriguing inverse association between abdominal adiposity
and CHD risk in men may be due to chance, a comparable
ﬁnding was recently reported for Alzheimer’s disease risk.
22
Interestingly, in the current study, the gender interaction was no
longer observed when the study population was stratiﬁed by
abdominal adiposity level, the p values for interaction being 0.31
and 0.77 respectively in the obese and the non-obese subjects
(not shown). Finally, there may be biological interactions
between the individual components of the MetS in women and
not or of less importance in men. In the current study, the
likelihood ratio of a model predicting CHD and including indi-
vidual MetS components plus two by two interaction terms was
signiﬁcantly better than the model without interactions in
women but not in men (data not shown).
The respective contribution of the MetS and of its individual
components for CHD risk remains a matter of debate.
23e25 In the
current study, several ﬁndings argue against the potential clinical
usefulness of the MetS to predict the risk of CHD. First, the
association between the MetS and CHD events was of lower
magnitude than that between elevated fasting glycaemiadthe
most signiﬁcant component- and CHD. Second, the MetS was no
longer associated with CHD after adjustment for its compo-
nents. Similar observations have been recently reported in
a limited sample of 1221 Swedish men over 70 years for total and
cardiovascular mortality, but CHD morbidity was not investi-
gated in that study.
26 By contrast, in the Cardiovascular Health
Study, the MetS as deﬁned by the 2001 NCEP-ATP III criteria
remained predictive of CHD and stroke even after adjustment for
its components, although this adjustment attenuated substan-
tially its HR.
27 Third, our study shows that the MetS failed to
improve in a clinically relevant manner discrimination for CHD
risk beyond baseline confounders not including the MetS
components. By contrast, discrimination was substantially
improved by the addition of the components of the MetS. This
latter ﬁnding re-emphasises that the classical risk factors remain
the cornerstone for CHD risk stratiﬁcation purposes.
The current study has some limitations. Analysis was based
on a single measurement of the MetS. The thresholds currently
used for the deﬁnition of the MetS may not be suitable for an
older population. Residual confounding cannot be excluded and
in particular, socioeconomic position from across the life-course
has been suggested to be an important confounder, at least
in British elderly women.
9 The current study includes well-
functioning, highly educated subjects and mostly Caucasians,
needing caution before extrapolating these results to the frailest
and other ethnic groups.
CONCLUSION
In summary, in this large prospective study of non-institution-
alised elderly men and women, the MetS was an independent
risk marker of CHD events especially in women. However, while
the individual components of the MetS improved signiﬁcantly
discrimination for CHD risk beyond baseline confounders, the
MetS did not. Therefore, a systematic assessment of the MetS
may not be suitable for CHD risk stratiﬁcation purposes in the
elderly.
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Model Harell-C index 95% CI p Value* NRI % p Value
Risk factors base model 0.706 0.705 to 0.707 ee e
+ MetSy 0.718 0.717 to 0.719 <0.001 3.12 0.06
+ Individual components of the MetS 0.761 0.760 to 0.762 <0.001 9.35 <0.001
The Three City Study.
The risk factors base model includes age, study center, educational level, living alone, incapacity in instrumental activities of daily living, smoking status, LDL cholesterol, statin treatment, and
gender as covariates.
*The 95% CI of the Harell-C indexes and difference between the Harell-C indexes were obtained after 1000 bootstrapping with replications.
yRevised 2005 National Cholesterol Education Program Adult Treatment Panel III criteria.
MetS, metabolic syndrome; NRI, net reclassiﬁcation improvement.
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